Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History VKTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics VKTX

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Viking Therapeutics Inc

VKTX
Current price
31.63 USD +0.86 USD (+2.79%)
Last closed 31.11 USD
ISIN US92686J1060
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 3 617 061 632 USD
Yield for 12 month -46.73 %
1Y
3Y
5Y
10Y
15Y
VKTX
21.11.2021 - 28.11.2021

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. Address: 9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

90.26 USD

P/E Ratio

Dividend Yield

Financials VKTX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures VKTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

-292 000 USD

Current Quarter

Last Quarter

EBITDA
Operating Margin TTM
Price to Earnings
Return On Assets TTM -11.74 %
PEG Ratio -0.030
Return On Equity TTM -14.40 %
Wall Street Target Price 90.26 USD
Revenue TTM
Book Value 7.54 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -1.16 USD
Diluted Eps TTM -1.16 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation VKTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -71.64
Price Book MRQ 4.03

Technical Indicators VKTX

For 52 Weeks

18.92 USD 81.73 USD
50 Day MA 27.65 USD
Shares Short Prior Month 28 474 422
200 Day MA 39.14 USD
Short Ratio 9.61
Shares Short 28 654 119
Short Percent 30.42 %